Woodline Partners’s Praxis Precision Medicines PRAX Stock Holding History
Bought
Maintained
Sold
Other funds holding PRAX
JT
PA
BBA
OAG
Woodline Partners's PRAX Position: Q2 2026 in Review
Woodline Partners held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 200,013 shares worth $67M. The position accounts for 0.21% of the portfolio, ranked #125.
Woodline Partners first reported a position in PRAX in Q4 2020 and has held it in 15 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.
- Woodline Partners held 200,013 shares of Praxis Precision Medicines worth $67M as of Q2 2026.
- Woodline Partners left its Praxis Precision Medicines share count unchanged in Q2 2026.
- Praxis Precision Medicines made up 0.21% of Woodline Partners's portfolio in Q2 2026, its #125 holding.
- Woodline Partners first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 15 quarters since.
- 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.